CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Lorazepam

劳拉西泮 杂质对照品Lorazepam Impurities

EP26 个杂质条目26 impurity entries

本页汇总 劳拉西泮 的 26 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 26 impurity reference standards of Lorazepam with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 劳拉西泮(Lorazepam)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studies[Changes in Test Methods for Internationalization in the Japanese Pharmacopoeia (Part 2): Establishment of a Quantitative Method for Lorazepam Using HPLC Analysis]
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan · 2021 · Maniwa A et al.  ·  PMID 34193656  ·  DOI
  2. 杂质研究Impurity studiesIsolation and identification of a new impurity in lorazepam substance
    Die Pharmazie · 2001 · Cepanec I et al.  ·  PMID 11817169
  3. 杂质研究Impurity studiesStability Study of Lorazepam Oral Solution Repackaged in Amber Colored ENFit Oral Syringes
    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025 · Owczarzak C et al.  ·  PMID 41112338  ·  DOI
  4. 分析方法Analytical MethodsLong-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers
    Hospital pharmacy · 2020 · Colsoul ML et al.  ·  PMID 32508356  ·  DOI
  5. 分析方法Analytical MethodsThe detection and quantification of lorazepam and its 3-O-glucuronide in fingerprint deposits by LC-MS/MS
    Journal of separation science · 2009 · Goucher E et al.  ·  PMID 19569106  ·  DOI

劳拉西泮 —— 原料药与杂质对照品Lorazepam — drug substance & impurities

共 26 个条目(含原料药本体)26 items incl. the drug substance
Lorazepam Impurity 1 (Lorazepam EP Impurity A) structure
EPA
劳拉西泮杂质1 (劳拉西泮EP杂质A)Lorazepam Impurity 1 (Lorazepam EP Impurity A)
Lorazepam Impurity 1 (Lorazepam EP Impurity A)
CAS No.2958-36-3
Chemical FormulaC13H9Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 2 (Lorazepam EP Impurity B) (Mixture of Enantiomers) structure
EPB
劳拉西泮杂质2 (劳拉西泮EP杂质B) (对映异构体混合物)Lorazepam Impurity 2 (Lorazepam EP Impurity B) (Mixture of Enantiomers)
Lorazepam Impurity 2 (Lorazepam EP Impurity B) (Mixture of Enantiomers)
CAS No.2848-96-6
Chemical FormulaC17H12Cl2N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 3 (Lorazepam EP Impurity C) structure
EPC
劳拉西泮杂质3 (劳拉西泮EP杂质C)Lorazepam Impurity 3 (Lorazepam EP Impurity C)
Lorazepam Impurity 3 (Lorazepam EP Impurity C)
CAS No.2955-37-5
Chemical FormulaC15H10Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 4 (Lorazepam EP Impurity D) (Mixture of Enantiomers) structure
EPD
劳拉西泮杂质4 (劳拉西泮EP杂质D) (对映异构体混合物)Lorazepam Impurity 4 (Lorazepam EP Impurity D) (Mixture of Enantiomers)
Lorazepam Impurity 4 (Lorazepam EP Impurity D) (Mixture of Enantiomers)
CAS No.54699-91-1
Chemical FormulaC15H10Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 16 (Lorazepam EP Impurity E) structure
EPE
劳拉西泮杂质16 (劳拉西泮EP杂质E)Lorazepam Impurity 16 (Lorazepam EP Impurity E)
Lorazepam Impurity 16 (Lorazepam EP Impurity E)
CAS No.93955-15-8
Chemical FormulaC15H8Cl2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 7 structure
7
劳拉西泮杂质7Lorazepam Impurity 7
Lorazepam Impurity 7
CAS No.773871-49-1
Chemical FormulaC15H10Cl2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 10 structure
10
劳拉西泮杂质10Lorazepam Impurity 10
Lorazepam Impurity 10
CAS No.14405-03-9
Chemical FormulaC15H10Cl3NO2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 11 structure
11
劳拉西泮杂质11Lorazepam Impurity 11
Lorazepam Impurity 11
CAS No.110032-65-0
Chemical FormulaC15H10Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 12 structure
12
劳拉西泮杂质12Lorazepam Impurity 12
Lorazepam Impurity 12
CAS No.91402-80-1
Chemical FormulaC15H10Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 13 structure
13
劳拉西泮杂质13Lorazepam Impurity 13
Lorazepam Impurity 13
CAS No.127930-80-7
Chemical FormulaC19H14Cl2N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Diazepam Impurity 13 structure
13
地西泮杂质13Diazepam Impurity 13
Diazepam Impurity 13
CAS No.1407522-30-8
Chemical FormulaC14H8Cl2N2
Purity>95%现货In stock
10mg25mg50mg100mg
Lorazepam Impurity 14 structure
14
劳拉西泮杂质14Lorazepam Impurity 14
Lorazepam Impurity 14
CAS No.84799-34-8
Chemical FormulaC17H12Cl2N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 15 structure
15
劳拉西泮杂质15Lorazepam Impurity 15
Lorazepam Impurity 15
CAS No.54643-79-7
Chemical FormulaC15H8Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Diazepam Impurity 15 structure
15
地西泮杂质15Diazepam Impurity 15
Diazepam Impurity 15
CAS No.63076-89-1
Chemical FormulaC15H11ClN2O3
Purity>95%现货In stock
10mg25mg50mg100mg
Lorazepam Impurity 18 structure
18
劳拉西泮杂质18Lorazepam Impurity 18
Lorazepam Impurity 18
CAS No.5600-85-1
Chemical FormulaC15H12Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 20 structure
20
劳拉西泮杂质20Lorazepam Impurity 20
Lorazepam Impurity 20
CAS No.52335-37-2
Chemical FormulaC15H9Cl4NO2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 23 structure
23
劳拉西泮杂质23Lorazepam Impurity 23
Lorazepam Impurity 23
CAS No.784-38-3
Chemical FormulaC13H9ClFNO
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 25 structure
25
劳拉西泮杂质25Lorazepam Impurity 25
Lorazepam Impurity 25
CAS No.152453-65-1
Chemical FormulaC15H10Cl2INO2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 27 structure
27
劳拉西泮杂质27Lorazepam Impurity 27
Lorazepam Impurity 27
CAS No.23441-87-4
Chemical FormulaC14H8Cl2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 29 structure
29
劳拉西泮杂质29Lorazepam Impurity 29
Lorazepam Impurity 29
CAS No.319-39-1
Chemical FormulaC13H9Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 38 structure
38
劳拉西泮杂质38Lorazepam Impurity 38
Lorazepam Impurity 38
CAS No.2891512-09-5
Chemical FormulaC19H14Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 39 structure
39
劳拉西泮杂质39Lorazepam Impurity 39
Lorazepam Impurity 39
CAS No.20838-77-1
Chemical FormulaC15H12Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 40 structure
40
劳拉西泮杂质40Lorazepam Impurity 40
Lorazepam Impurity 40
CAS No.2888-63-3
Chemical FormulaC15H12Cl2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 48 structure
48
劳拉西泮杂质48Lorazepam Impurity 48
Lorazepam Impurity 48
CAS No.98601-72-0
Chemical FormulaC13H9Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 49 structure
49
劳拉西泮杂质49Lorazepam Impurity 49
Lorazepam Impurity 49
CAS No.406684-53-5
Chemical FormulaC13H9Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg
Lorazepam Impurity 50 structure
50
劳拉西泮杂质50Lorazepam Impurity 50
Lorazepam Impurity 50
CAS No.1406927-99-8
Chemical FormulaC13H9Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

劳拉西泮 —— 研究文献与合成路线Lorazepam — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 劳拉西泮 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Lorazepam. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. The 60-day temperature-dependent degradation of midazolam and Lorazepam in the prehospital environment
    McMullan JT, Pinnawin A, Jones E, et al. · Prehospital emergency care · 2013 · 被引 22cited 22
  2. [Characterization of lorazepam and oxazepam by the thermal behavior of their degradation product]
    Chauvet A · Annales pharmaceutiques francaises · 1995 · 被引 1cited 1
  3. Isolation and identification of a new impurity in lorazepam substance
    Cepanec I, Mikuldas H, Litvić M, et al. · Die Pharmazie · 2001

合成与制备工艺专利Synthesis & process patents

  1. Purification process of lorazepam
    LOPUCH JOZEF, PROKSA BOHUMIL, VANDAK DUSAN · 公开号 CZ20041138CZ20041138 · 2006
  2. Lorazepam dripping pills and its preparation process
    QIAN JIN XU · 公开号 CN1546035CN1546035 · 2004
  3. Dropping pills containing lorazepam and method for preparing the same
    YONGQIANG LI, YONGFENG ZHENG · 公开号 CN101194908CN101194908 · 2008
  4. PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM
    LIFSHITZ IGOR · 公开号 WO0166062WO0166062 · 2001
  5. PROCESS FOR PREPARING PURE CRYSTALLINE LORAZEPAM
    LIFSHITZ IGOR · 公开号 EP1265875EP1265875 · 2002

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

劳拉西泮 杂质谱研究要点Lorazepam — impurity profiling notes

下面这些是拿到 劳拉西泮 的 26 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 26 impurity entries for Lorazepam, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances